A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Macquarie University ( Site 0033), Macquarie University

Alfred Health ( Site 0031), Melbourne

Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, Milan

Henry Ford Health System ( Site 0002), Detroit

ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0091), Siena

Next Oncology ( Site 0001), San Antonio

Chaim Sheba Medical Center ( Site 0020), Ramat Gan

FALP-UIDO ( Site 0100), Santiago

Bradfordhill-Clinical Area ( Site 0101), Santiago

Hadassa Ein Karem Medical Center ( Site 0022), Jerusalem

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0003), Hackensack

BC Cancer - Vancouver Center ( Site 0010), Vancouver

Princess Margaret Cancer Centre ( Site 0011), Toronto

Seoul National University Hospital ( Site 0061), Seoul

Asan Medical Center ( Site 0060), Seoul

Hospital Clinic i Provincial ( Site 0041), Barcelona